Digest Network Come funziona
Network
/
Società
Ze
Non verificato

Zetagen Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

12 comunicati stampa

Guarda tutti i comunicati
11/06/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
CORRECTING and REPLACING Zetagen Therapeutics Presents Phase 2a Results at ASCO for Investigational ZetaMet™ (Zeta BC 003) in Metastatic Breast Cancer Patients with Lytic Bone Lesions
Fonte
Zetagen Therapeutics, Inc.
Emittente
Business Wire
1.00
0
09/06/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Zetagen Therapeutics Presents Phase 2a Results at ASCO for Investigational ZetaMet™ (Zeta BC 003) in Metastatic Breast Cancer Patients with Lytic Bone Lesions
Fonte
Zetagen Therapeutics, Inc.
Emittente
Business Wire
1.00
0
25/11/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Zetagen Therapeutics Closes Oversubscribed Series B1 Round on Strength of Promising Phase 2a Data and Compelling Pipeline
Fonte
Zetagen Therapeutics, Inc.
Emittente
Business Wire
1.00
0
04/11/2025
Eventi
Fiere
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Zetagen Therapeutics to Present Promising Preclinical Data at SABCS: Zeta-BC-007 Demonstrates Superior Tumoricidal Activity and Survival Benefit in Breast Cancer Model
Fonte
Zetagen Therapeutics, Inc.
Emittente
Business Wire
1.00
0
04/11/2025
Eventi
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Sanità
Zetagen Therapeutics to Present Preliminary Results from Phase 2 Clinical Trial Targeting Metastatic Breast Cancer to Bone at the 2025 San Antonio Breast Cancer Symposium
Fonte
Zetagen Therapeutics, Inc.
Emittente
Business Wire
1.00
0
28/07/2025
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Industria
Zetagen Therapeutics Secures Composition-of-Matter Patents from USPTO for Novel Breast Cancer Platform
Fonte
Zetagen Therapeutics, Inc.
Emittente
Business Wire
1.00
0
17/06/2025
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Eventi
Industria
Zetagen Therapeutics Announces Peer-reviewed Publication of In-Vivo Dose Optimization Findings for ZetaMast™ (Zeta-MBC-005) for Triple Negative Breast Cancer Liver Metastases
Fonte
Zetagen Therapeutics, Inc.
Emittente
Business Wire
1.00
0
06/05/2025
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Zetagen Therapeutics Announces Successful Completion of Enrollment in Phase 2a Clinical Study of ZetaMet™ (Zeta-BC-003) Metastatic Breast Cancer
Fonte
Zetagen Therapeutics, Inc.
Emittente
Business Wire
1.00
0
08/01/2025
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Zetagen Therapeutics Expands IP Portfolio, Achieving a Milestone of 64 Worldwide Patents in 2024
Fonte
Zetagen Therapeutics, Inc.
Emittente
Business Wire
1.00
0
10/12/2024
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Zetagen Therapeutics Shares In-vivo Dose Optimization Data of ZetaMAST™ (Zeta-MBC-005) Metastatic Breast Cancer in Liver
Fonte
Zetagen Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0